Clinical evaluation of a dried blood spot method for determination of mycophenolic acid in renal transplant patients

Clinical Biochemistry

Volumn 46, Issue 18, 2013, Pages 1905-1908

  Arpini, Janaíne ^a   Antunes, Marina Venzon ^a   Pacheco, Larissa Sgaria ^b   Gnatta, Diego ^b   Rodrigues, Mariana Ferraz ^b   Keitel, Elizete ^b   Linden, Rafael ^a  

^a UNIVERSIDADE FEEVALE   (Brazil)

^b Nephrology Unit   (Brazil)

Author keywords

Dried blood spots; HPLC; Mycophenolic acid; Therapeutic drug monitoring

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; BLOOD LEVEL; CLINICAL EVALUATION; DRIED BLOOD SPOT TESTING; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

DRIED BLOOD SPOTS; HPLC; MYCOPHENOLIC ACID; THERAPEUTIC DRUG MONITORING;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRIED BLOOD SPOT TESTING; DRUG MONITORING; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 84889645848     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.10.011     Document Type: Article

References (10)

1. Jeong H., Kaplan B. Therapeutic monitoring of Mycophenolate mofetil. Clin J Am Soc Nephrol 2007, 2(1):184-191.
2. van Gelder T., Meur Y.L., Shaw L.M., Oellerich M., DeNofrio D., Holt C., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28(2):145-154.
3. Prémaud A., Debord J., Rousseau A., Le Meur Y., Toupance O., Lebranchu Y., et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet 2005, 44(8):837-847.
4. Sommerer C., Müller-Krebs S., Schaier M., Glander P., Budde K., Schwenger V., et al. Pharmacokinetic and pharmacodynamic analysis of enteric coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010, 69(4):346-357.
5. Edelbroek P.M., van der Heijden J., Stolk L.M. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009, 31(3):327-336.
6. Wilhelm A.J., Den Burger J.C., Chahbouni A., Vos R.M., Sinjewel A. Analysis of mycophenolic acid in dried blood spots using reversed phase high performance liquid chromatography. J Chromatogr B 2009, 877(30):3916-3919.
7. Antunes M.V., Paris C., Thiele K.O., Keitel E., Garcia V.D., Linden R. Determinação de ácido micofenólico em plasma por cromatografia líquida de alta eficiência com detector de arranjo de diodos (CLAE-DAD). Lat Am J Pharm 2009, 28(4):495-500.
8. Langman L.J., LeGatt D.F., Yatscoff R.W. Blood distribution of mycophenolic acid. Ther Drug Monit 1994, 16(6):602-607.
9. Orsini J.J., Yeman J., Caggana M., Bodamer O.A., Mühl A. Semi-quantitative method for determination of hematocrit in dried blood spots, using data collected in HPLC hemoglobin variant testing. Clin Chim Acta 2010, 411(11-12):894-895.
10. Capiau S., Stove V.V., Lambert W.E., Stove C.P. Prediction of the hematocrit of dried blood spots via potassium measurement on a routine clinical chemistry analyzer. Anal Chem 2013, 85(1):404-410.